CN104447721A - Canagliflozin anhydrous compound - Google Patents
Canagliflozin anhydrous compound Download PDFInfo
- Publication number
- CN104447721A CN104447721A CN201310415190.9A CN201310415190A CN104447721A CN 104447721 A CN104447721 A CN 104447721A CN 201310415190 A CN201310415190 A CN 201310415190A CN 104447721 A CN104447721 A CN 104447721A
- Authority
- CN
- China
- Prior art keywords
- clean
- anhydrous compound
- kan gelie
- kan
- gelie
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960000784 canagliflozin anhydrous Drugs 0.000 title abstract 2
- -1 Canagliflozin anhydrous compound Chemical class 0.000 title 1
- 239000013078 crystal Substances 0.000 claims abstract description 28
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 9
- 239000003814 drug Substances 0.000 claims abstract description 7
- 150000001875 compounds Chemical class 0.000 claims description 27
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 8
- 238000002425 crystallisation Methods 0.000 claims description 6
- 230000008025 crystallization Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 238000003756 stirring Methods 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 229910016523 CuKa Inorganic materials 0.000 claims description 3
- LLZZJKVZPXDSOR-UHFFFAOYSA-N acetonitrile;butan-2-one Chemical compound CC#N.CCC(C)=O LLZZJKVZPXDSOR-UHFFFAOYSA-N 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 3
- 238000001035 drying Methods 0.000 claims description 3
- 239000000706 filtrate Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 239000011259 mixed solution Substances 0.000 claims description 3
- 239000011550 stock solution Substances 0.000 claims description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 3
- 238000009413 insulation Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 7
- XTNGUQKDFGDXSJ-ZXGKGEBGSA-N Canagliflozin Chemical compound CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 XTNGUQKDFGDXSJ-ZXGKGEBGSA-N 0.000 abstract description 5
- 201000010099 disease Diseases 0.000 abstract description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 3
- 230000003287 optical effect Effects 0.000 abstract description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract description 3
- 229960001713 canagliflozin Drugs 0.000 abstract 1
- VHOFTEAWFCUTOS-TUGBYPPCSA-N canagliflozin hydrate Chemical compound O.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1.CC1=CC=C([C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C=C1CC(S1)=CC=C1C1=CC=C(F)C=C1 VHOFTEAWFCUTOS-TUGBYPPCSA-N 0.000 abstract 1
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- 230000036765 blood level Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000000825 pharmaceutical preparation Substances 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 208000002249 Diabetes Complications Diseases 0.000 description 3
- 206010012655 Diabetic complications Diseases 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 201000001421 hyperglycemia Diseases 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 238000000634 powder X-ray diffraction Methods 0.000 description 3
- 208000011580 syndromic disease Diseases 0.000 description 3
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 2
- 206010012689 Diabetic retinopathy Diseases 0.000 description 2
- 102000018711 Facilitative Glucose Transport Proteins Human genes 0.000 description 2
- 108091052347 Glucose transporter family Proteins 0.000 description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 208000033679 diabetic kidney disease Diseases 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 description 2
- 201000008980 hyperinsulinism Diseases 0.000 description 2
- 230000001631 hypertensive effect Effects 0.000 description 2
- 208000006575 hypertriglyceridemia Diseases 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 230000003178 anti-diabetic effect Effects 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000005286 illumination Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention belongs to the technical field of medicine, and in particular to a Canagliflozin anhydrous crystal form and a preparation method thereof. The Canagliflozin prepared by the invention has the advantages of chemical purity of 99.9%, maximum is less than 1 per thousand, optical purity of up to 99.96% ee and good stability. The invention also relates to application of the crystal form composition to preparation of medicaments for treating type 2 diabetes and related diseases.
Description
Technical field
The invention belongs to medical art, be specifically related to clean anhydrous crystal forms of Kan Gelie and preparation method thereof, the invention still further relates to the application of composition in the disease treatments such as diabetes B using this compound.
Background technology
Patent WO2005/012326 is disclosed as the compound group of sodium dependent glucose transporter (SGLT) inhibitor, and these compounds are for the therepic use of process diabetes, obesity, diabetic complication etc.Be described in 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-the fluorophenyl)-2-thienyl methyl] benzene of the formula (I) of patent WO2005/012326:
Generally speaking, in order to commercial use, importantly product should possess the good character of operation.In addition, also need this product manufacturing pure matter and crystal type, make formula can meet strict requirement pharmaceutically and specification.
And it is desirable to this product and should be and can be easy to filter and easily dry pattern.In addition, it is desirable to economically special preservation condition can be stable product within the time of an elongated segment.
But the crystal type that will obtain formula (I) compound from organic solvent has difficulties.
Have now found that and the reproducible method of commercial size can produce the anhydrous compound of crystalline form (I).
Summary of the invention
The invention provides the material of anhydrous compound crystal type as novelty of formula (I) compound, particularly with pharmaceutically acceptable pattern.
The present inventor has found from moisture solvent, crystallization to go out formula (I) compound, and this formula (I) compound crystal type possesses the good character of operation and characteristic.
Accordingly, the present invention relates to:
A kind of crystal type 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] benzene anhydrous compound.
A kind of crystal type 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] benzene anhydrous compound, be characterised in that powder x-ray diffraction collection of illustrative plates (powder x-ray diffraction pattern), this collection of illustrative plates comprises the following 2 θ values using CuKa radiation measurement: 3.780 ± 0.2,7.660 ± 0.2,15.360 ± 0.2,17.040 ± 0.2,17.900 ± 0.2,18.820 ± 0.2,21.640 ± 0.2,23.040 ± 0.2,24.280 ± 0.2,26.360 ± 0.2,27.400 ± 0.2.
A kind of in order to prepare the method for crystal type 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] benzene semihydrate, it comprises the solution forming 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] benzene, and utilizes precipitation or recrystallize from this anhydrous compound of this solution crystallization.
A kind of medical composition, includes crystal type 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] the benzene anhydrous compound of effective amount and pharmaceutically acceptable carrier.
One is used for the treatment of or delays diabetes, diabetic retinopathy, diabetic neuropathy, diabetic nephropathy, retardance wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, the blood level of lipid acid raises, the blood level of glycerine raises, hyperlipidemia, fat, hypertriglyceridemia, X syndrome (syndrome X), diabetic complication, the method of arteriosclerosis or hypertensive progress or morbidity, it comprises crystal type 1-(β-D-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienyl methyl] the benzene semihydrate of dispensing treatment significant quantity.
As mentioned above, the present invention comprises some solid state crystalline form.There is multiple method for characterizing this pattern, and the present invention not should by selected method or be used for characterization the compounds of this invention equipment and limit.Such as, with X-ray diffracting spectrum, in experimental patterns, this diffraction peak intensities can change to some extent, as being known in the art, mainly results from the preferred orientation (non-any orientation of this crystallization) of prepared sample.Therefore, person skilled in the art can understand, and category of the present invention must consider the change degree of feature.
The clean anhydrous compound crystal of this Kan Gelie, adopts D/Max-2500.9161 type x-ray diffractometer to measure, condition determination: Cu Ka target, tube voltage 40KV, tube current 100mA.X-ray powder diffraction charateristic avsorption band (2 θ) and D value as follows.
In the present invention, the mensuration of 2 θ values uses light source, and precision is ± 0.2 °, and therefore represent above-mentioned got value and allowed certain reasonably limit of error, its limit of error is ± 0.2 °.
When infrared spectrogram measures, the correction polystyrene film of instrument, meets the regulation of Chinese Pharmacopoeia.
This crystal formation infrared spectrogram (KBr pressed disc method mensuration), at 3422 ± 5cm
-1; 3099 ± 5cm
-1; 2875 ± 5cm
-1; 1547 ± 2cm
-1; 1437 ± 2cm
-1; 1158 ± 2cm
-1there is characteristic peak at place.
The fusing point of this crystal formation is 222 DEG C-222.5 DEG C, measures by the method for Chinese Pharmacopoeia, and this is that those skilled in the art are in common knowledge.
Another object of the present invention, discloses the preparation method of the clean anhydrous compound crystal of Kan Gelie,
Specifically comprise the following steps:
Kan Gelie adds in 4-5 times of (weigh-volume ratio) water only, and in the above-mentioned aqueous solution, add the dimethyl formamide (DMF) of the clean 0.5%-1% of Kan Gelie, stir 30 minutes, filter, filtrate is cooled to 10 DEG C-15 DEG C, for subsequent use.
The mixed solution of clean for Kan Gelie 18-20 times of acetonitrile-methyl ethyl ketone=5-6:5-4 is cooled to 10 DEG C-15 DEG C, adds above-mentioned stock solution, insulation 16-20 hour, crystallization, filter, drying obtains.Chemical purity is up to 99.9%, and maximum contaminant is less than 1 ‰, and optical purity is up to more than 99.9%ee.
Kan Gelie used is clean, and the method synthesis that reference WO2005/012326 provides, the Kan Gelie of synthesis is clean, and its chemical structure, through determination of elemental analysis, proves that chemical structure is correct.
Another object of the present invention, provides the composition comprising the clean anhydrate of Kan Gelie that Kan Gelie clean anhydrate crystal and one or more pharmaceutically acceptable carriers form.
Crystalline compound of the present invention has the activity as sodium dependent glucose transporter inhibitors, and shows splendid blood sugar decreasing effect.
Crystal type expection of the present invention is useful in the following areas: treatment, prevent or delay diabetes (1 type and diabetes B etc.), diabetic complication is (as diabetic retinopathy, diabetic neuropathy, diabetic nephropathy), post prandial hyperglycemia, retardance wound healing, insulin resistance, hyperglycemia, hyperinsulinemia, the blood level of lipid acid raises, the blood level of glycerine raises, hyperlipidemia, fat, hypertriglyceridemia, X syndrome, arteriosclerosis or hypertensive progress or morbidity.
Crystal type of the present invention or its pharmaceutically acceptable salt can oral or parenteral administration, and pharmaceutical preparation pattern that can be suitable and using.Suitable pharmaceutical preparation for oral administration medicine supplying comprises, and such as, solid formulation is as tablet, granula, capsule and powder, or liquid formulation, suspension formulation, emulsification preparation etc.Suitable pharmaceutical preparation for parenteral administration comprises, such as, and suppository; Injection formulations or intravenous drip preparations, utilize distilled water for injection, physiological saline solution or D/W; And suction preparation.
Medical composition herein will in every dose unit, i.e. tablet, capsule, powder, injection, suppository, amounts (teaspoonful) etc., comprise oneself about 0.01 mg/kg of activeconstituents extremely about 100 mg/kg body weight (preferably oneself about 0.01 mg/kg extremely about 50 mg/kg; And more preferably from about 0.01 mg/kg extremely about 30 mg/kg), and dosage about 0.01 mg/kg/day extremely about 100 mg/kg/day (preferably from about 0.01 mg/kg/day extremely about 50 mg/kg/day, and more preferably from about 0.01 mg/kg/day extremely about 30 mg/kg/day) certainly can be given.The method that treatment is described in illness of the present invention also can use the medical composition of crystal type and the pharmaceutically acceptable carrier comprised as defined herein and implement.This dosage form will comprise oneself about 0.01 mg/kg of activeconstituents extremely about 100 mg/kg (preferably oneself about 0.01 mg/kg extremely about 50 mg/kg, and more preferably from about 0.01 mg/kg extremely about 30 mg/kg), and any pattern being applicable to selected dispensing pattern can be formed.But this dosage can be different according to the severity of dosing way, individual demand, wish treatment symptom and the compound used.The usage of dispensing every day or rear periodically medication (post-periodicdosing) can be used in.
If desired, time, crystal type of the present invention can use with one or more other antidiabetics, antihyperglycemic agents and/or other diseases therapeutic combination.The compounds of this invention and this other treatment agent can same dosage form or the oral dosage form separated or inject be offerd medicine.
The dosage of this therapeutical agent can be complied with, such as, the age, body weight, conditions of patients, dosing way, different from dosage forms.
This medical composition can oral administration medicine supplying to mammals, comprise the mankind, ape, dog, with such as tablet, capsule, granula or powder, or the dosage forms of the injection type of parenteral administration or interanasal administration or skin paste formulation.
Stability test
The stability of contriver to crystal formation of the present invention is studied, and investigation condition is high temperature (60 DEG C ± 2 DEG C), strong illumination (4500Lx ± 500lx), and high humidity (92.5% ± 5%) inspection target is outward appearance, content and related substance.
Result: from 0-10 days under high light, high temperature, super-humid conditions, outward appearance, related substance, content do not change, and illustrate that chemical stability is good, are applicable to manufacture and the standing storage of pharmaceutical preparation.
Embodiment
Below in conjunction with embodiment, the present invention is described further, makes professional and technical personnel in the field better understand the present invention.Embodiment is only indicative, never means that it limits the scope of the invention by any way.
embodiment 1
In the 500ml reaction flask that stirring, thermometer, condenser are housed, add clean and 300 ml waters of 60 Ke Kangelie, in the above-mentioned aqueous solution, add 0.5 gram of dimethyl formamide (DMF), stirs 30 minutes, filtration, filtrate is cooled to 12 DEG C, for subsequent use.
The mixed solution of 1150ml acetonitrile-methyl ethyl ketone=5:5 is cooled to 13 DEG C, adds above-mentioned stock solution under stirring, be incubated 18 hours, crystallization, filter, drying obtains white crystals 54.4 grams.Purity 99.9% (HPLC normalization method), optical purity 99.96%ee (chirality HPLC).
INSTRUMENT MODEL and condition determination: Rigaku D/max 2500 type diffractometer; CuKa, 40Kv, 100mA; 2 θ sweep limit: 0-50
°.
Claims (6)
1. the clean anhydrous compound of Kan Gelie shown in formula I,
The crystal of the clean anhydrous compound of described Kan Gelie, in measuring as characteristic X-ray powder with CuKa ray, its collection of illustrative plates has following 2 θ diffraction angle and d value,
The error of 2 θ diffraction angle is ± 0.2.
2. the clean anhydrous compound crystal of Kan Gelie described in claim 1, infrared spectrogram, pellet technique measures, at 3422 ± 5cm
-1; 3099 ± 5cm
-1; 2875 ± 5cm
-1; 1547 ± 2cm
-1; 1437 ± 2cm
-1; 1158 ± 2cm
-1there is characteristic peak at place.
3. the preparation method of the clean anhydrous compound crystal of Kan Gelie described in claim 1, by Kan Gelie being added only in 4-5 times of (weight or measurement (WM) ratio) water, the dimethyl formamide (DMF) of the clean 0.5%-1% of Kan Gelie is added in the above-mentioned aqueous solution, stir 30 minutes, filter, filtrate is cooled to 10 DEG C-15 DEG C, for subsequent use, then, the mixed solution of clean for Kan Gelie 18-20 times of acetonitrile-methyl ethyl ketone=5-6:5-4 is cooled to 10 DEG C-15 DEG C, adds above-mentioned stock solution, insulation 16-20 hour, crystallization, filter, drying obtains.
4. the composition of the clean anhydrous compound of Kan Gelie formed containing the clean anhydrous compound crystal of Kan Gelie described in claim 1 and one or more pharmaceutically acceptable carriers.
5. composition according to claim 4, is characterized in that said composition is for the preparation of tablet.
6. the clean anhydrous compound crystal of Kan Gelie described in claim 1 is manufacturing the application in treatment diabetes B medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310415190.9A CN104447721A (en) | 2013-09-13 | 2013-09-13 | Canagliflozin anhydrous compound |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201310415190.9A CN104447721A (en) | 2013-09-13 | 2013-09-13 | Canagliflozin anhydrous compound |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN104447721A true CN104447721A (en) | 2015-03-25 |
Family
ID=52894540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201310415190.9A Pending CN104447721A (en) | 2013-09-13 | 2013-09-13 | Canagliflozin anhydrous compound |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104447721A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016136830A1 (en) * | 2015-02-27 | 2016-09-01 | 田辺三菱製薬株式会社 | Novel crystal of 1-(β-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene |
| WO2016191173A1 (en) * | 2015-05-22 | 2016-12-01 | Janssen Pharmaceutica Nv | Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol |
-
2013
- 2013-09-13 CN CN201310415190.9A patent/CN104447721A/en active Pending
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016136830A1 (en) * | 2015-02-27 | 2016-09-01 | 田辺三菱製薬株式会社 | Novel crystal of 1-(β-d-glucopyranosyl)-4-methyl-3-[5-(4-fluorophenyl)-2-thienylmethyl]benzene |
| WO2016191173A1 (en) * | 2015-05-22 | 2016-12-01 | Janssen Pharmaceutica Nv | Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol |
| TWI710568B (en) * | 2015-05-22 | 2020-11-21 | 比利時商健生藥品公司 | Anhydrous crystalline form of (1s)-1,5-anhydro-1-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-d-glucitol |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102675380A (en) | Crystalline form of 1- (beta-D-glucopyranosyl) -4 -methyl- 3- [5- (4 -fluorophenyl) -2-thienylmethyl] benzene hemihydrate | |
| JPS5843996A (en) | Stable s-adenosylmethionine salts, manufacture and therapeutical composition containing them as active components | |
| JP2022503890A (en) | A salt formed by 2- (1-acyloxy-N-pentyl) benzoic acid and a basic amino acid or aminoguanidine, and a method and use thereof. | |
| JP6343000B2 (en) | Composition for preventing or treating atopic dermatitis containing eugenol as an active ingredient | |
| CN107311915A (en) | A kind of salicylic acid organic pharmaceutical co-crystal and preparation method thereof | |
| CN103919778A (en) | Application of curcumin analog S1 containing piperidone structure in preparation of anti-inflammation drugs | |
| CN103833713A (en) | Nicousamide compound crystal form III, preparation method, pharmaceutical composition and application thereof | |
| JP7362646B2 (en) | cocrystal | |
| CN104447721A (en) | Canagliflozin anhydrous compound | |
| EP3653603A1 (en) | Fenlean (flz) crystal g form, preparation method, and composition and use thereof | |
| CN104447722A (en) | Canagliflozin compound | |
| EP3904335A1 (en) | Acetylsalicylic acid derivative and application thereof | |
| CN104945455B (en) | Tonka bean camphor glycosides compounds, its preparation method and pharmaceutical composition and purposes | |
| CN104418818B (en) | Parecoxib sodium anhydrous compound | |
| CN113679728B (en) | A kind of sulfonamide compound and its application in the preparation of medicine for treating diabetes and complications | |
| CN110872280A (en) | Application of flavone C-glycoside monomeric compound | |
| CN102731430B (en) | Novel febuxostat crystal form, its preparation method and application thereof | |
| CN110128429A (en) | A kind of silaenafil-acesulfame potassium salt form and its preparation method and application | |
| CN115259994B (en) | DPI-organic acid double salt and preparation method and application thereof | |
| CN105367622B (en) | A kind of argatroban compound | |
| RU2575923C2 (en) | Organic salts of bromfenac and method for producing them, composition containing them, and using them | |
| CN109988216B (en) | Betulin crystal D-type substance, preparation method, composition and application thereof | |
| CN104447751A (en) | Tofacitinib compound | |
| CN105541946A (en) | Adenosine cyclophosphate crystalline compound | |
| CN118812404A (en) | Vitamin D co-crystal and its preparation method and application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20150325 |
|
| WD01 | Invention patent application deemed withdrawn after publication |